Peer Review History

Original SubmissionMarch 28, 2023
Decision Letter - Benjamin M. Liu, Editor

PONE-D-23-07664Peptide barcode of multi drug resistant strains of Neisseria gonorrhoeae isolated from patients in ThailandPLOS ONE

Dear Dr. Arpornsuwan

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 09 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Benjamin M. Liu, MBBS, PhD, D(ABMM), MB(ASCP)

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following: 

● The name of the colleague or the details of the professional service that edited your manuscript

● A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

● A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

6. Please upload a new copy of Figures 1 and 2 as the detail is not clear. Please follow the link for more information: " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"

7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Reviewer #3: Partly

Reviewer #4: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: N/A

Reviewer #4: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Summary : It is a very interesting and relevant topic. Determining the antibiotic susceptibility of Neisseria gonorrhoeae by mass spectrometry(MS) will help in easy and early detection of antibiotic resistance and hence efficient treatment of patients. Identification of biomarkers of resistance is also very useful.

Over all Impression: The study combines two research questions. First, generating the peptide barcodes for the different groups of antibiotic resistant Neisseria gonorrhoeae, secondly discovering the peptide biomarker of the antibiotic resistance by LCMS. The results, data and statistical analysis of both the experiments have not been presented adequately in the manuscript.

Major issues:

1. The result part of the MALDI-TOF peptide barcoding , from line number 203, does not clearly provide clear information and data regarding the differences in the peaks of the spectra of the different antibiotic resistance groups mentioned in the study. The Figure 1 is not clear and does not mention the above information. The statistical analysis and Odd's ratio for the same is not reported.

2. Which test of statistical analysis for the LCMS test has been done? The figures of the of the LCMS tests are not very clear.

Minor issues: I suggest that the authors hire a copy editor.

The manuscript deals with important topics of detection of antibiotic resistance by MALDITOF and discovering peptide biomarker of antibiotic resistance by LCMS. If the authors can provide the aforementioned details, it will be a valuable contribution to the research in antibiotic resistance.

Reviewer #2: 1. Novelty statement should be included, as identified 9 peptides are already known for their function in N. gonorrhoeae.

2. What are the Inclusion and Exclusion criteria?

3. What are the limitations of the study?

4. Why sample size is small?

-------------

Reviewer #3: 1. In the abstract and entire document, the name "Neisseria gonorrhoea" should all be typed in italics

2. Line 39, insert "of" between prevalence and infection.

3. line 56 remove hyphen from the word "de-creased"

4. Line 70, include year for the citation mentioned.

5. Line 96, the initial sentence can be re-written as "Sixty-three of the 91 isolates showed resistance to ........"

6. Line 112 remove hyphen from the word "performed"

7. Change "E test" to "E-test"

8. In section 2.5, I think is will be appropriate to describe or provide more detail on how the different bacterial groups were pooled together.

9. Line 300, use the word "consistent"

10. IMPORTANT COMMENT

There appears to be a significant missing link in the results presented in this study. The results obtained in the MIC determination using the E-test strip is not shown. The authors should present the result and further correlate with the peptidome obtained for the bacterial isolates.

This will provide a further validation of the use of the MALDI-TOF as suggested by the authors.

Reviewer #4: 1. There are some language and grammatical errors throughout the manuscript text that should be corrected.

2. Please define the abbreviations at the first mention of them in the text for example, IRB in line 93; PPNG: in line 97.

3. The data of Table 1 is repeated in the text, so this table could be deleted.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Dr. Ayodele Oluwaseun AJAYI

Reviewer #4: Yes: Mohammad Hossein Ahmadi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

PONE-D-23-07664

Peptide barcode of multi drug resistant strains of Neisseria gonorrhoeae isolated from patients in Thailand

Reviewer #1: Summary: It is a very interesting and relevant topic. Determining the antibiotic susceptibility of Neisseria gonorrhoeae by mass spectrometry (MS) will help in easy and early detection of antibiotic resistance and hence efficient treatment of patients. Identification of biomarkers of resistance is also very useful.

Overall Impression: The study combines two research questions. First, generating the peptide barcodes for the different groups of antibiotic resistant Neisseria gonorrhoeae, secondly discovering the peptide biomarker of the antibiotic resistance by LC-MS. The results, data and statistical analysis of both the experiments have not been presented adequately in the manuscript.

Major issues:

1. The result part of the MALDI-TOF peptide barcoding, from line number 203, does not clearly provide clear information and data regarding the differences in the peaks of the spectra of the different antibiotic resistance groups mentioned in the study. The Figure 1 is not clear and does not mention the above information. The statistical analysis and Odd's ratio for the same is not reported.

Ans. More informations regarding differences in the Maldi-TOF mass spectra of the different antibiotic resistance groups (Figure 1) and statistical analysis were added in Material and Method section (Line 135-142) and Result section (Line 222-230; Line 236-243).

2. Which test of statistical analysis for the LC-MS test has been done? The figures of the LC-MS tests are not very clear.

Ans. More informations regarding statistical analysis for the LC-MS data by DecyderMS and Mascot were added in Material and Method section (Line 167-174; Line 179-181) and Result section (Line 254-259; Line 261-262). In addition, the peptidomic heatmap, principal component analysis (PCA) and analysis of variance (ANOVA) analysis generated by Metaboanalyst 5.0 were added into Material and Method section (Line 179-181) and Result section (Line 261-262; Line 264-265; Line 267-268).

3. Minor issues: I suggest that the authors hire a copy editor.

Ans. This manuscript was corrected by The Professional editor under the program of Research clinic that supported by Faculty of Allied Health Sciences Thammasat University.

4. The manuscript deals with important topics of detection of antibiotic resistance by Maldi-TOF and discovering peptide biomarker of antibiotic resistance by LC-MS. If the authors can provide the aforementioned details, it will be a valuable contribution to the research in antibiotic resistance.

Ans. As mentioned in Line 254-259. Previous studies have reported the detection of antibiotic resistance bacteria based on peptide barcode differences [18-21]. However, the specific antibiotic resistance peptides on MALDI-TOF mass spectra are difficult to identify due to their low abundance or high molecular weights. LC-MS/MS was therefore used to improve the identification and quantification of potential peptide biomarkers with greater dynamic range, higher resolution, reproducibility and accuracy [23].

Reviewer #2:

1. Novelty statement should be included, as identified 9 peptides are already known for their function in N. gonorrhoeae.

Ans. The statement is added (Line 351-357). Peptide biomarkers of antibiotic resistance were associated with resistance enzymes including beta-lactamases, kanR and aminoglycoside modifying enzyme [20]. Some of these resistance peptides were encoded by gene cassettes in the bacterial genomes [21]. However, most of the bacterial peptides were generated by protein degradation [36]. Nine unique peptides were detected in each antibiotic resistant group that originated from nine proteins. These peptides could serve as specific biomarker candidates for AZ, C, CP, CT and CPT-resistant N. gonorrhoeae.

2. What are the Inclusion and Exclusion criteria?

Ans. There is no Inclusion and Exclusion criteria for collecting multidrug resistant strains of Neisseria gonorrhoeae. We used the antibiotic-resistant N. gonorrhoeae samples collected by the Sexually Transmitted Infection Cluster, Bureau of AIDS TB and STIs, Department of Disease Control, Ministry of Public Health, Thailand since January 2019 to December 2021.

3. What are the limitations of the study?

Ans. The limitation of the study is sample size. Although the the collecting time was 2 years (January 2019 to December 2021), only 93 samples were obtained.

4. Why sample size is small?

Ans. Sample size is a limitation of this study. As shown in Material and Method section, only 93 samples were collected during January 2019 to December 2021.

-------------

Reviewer #3:

1. In the abstract and entire document, the name "Neisseria gonorrhoea" should all be typed in italics

Ans. The name "Neisseria gonorrhoea" is now typed in italics both in the abstract and entire document.

2. Line 39, insert "of" between prevalence and infection.

Ans. "of" is inserted between prevalence and infection

3. line 56 remove hyphen from the word "de-creased"

Ans. hyphen from the word "de-creased" is removed.

4. Line 70, include year for the citation mentioned.

Ans. The year “2014” is added for the citation mentioned.

5. Line 96, the initial sentence can be re-written as "Sixty-three of the 91 isolates showed resistance to ........"

Ans. This sentence is re-written.

6. Line 112 remove hyphen from the word "performed"

Ans. Hyphen was removed from the word "performed"

7. Change "E test" to "E-test"

Ans. "E test" were changed to "E-test" through the manuscript.

8. In section 2.5, I think is will be appropriate to describe or provide more detail on how the different bacterial groups were pooled together.

Ans. More detail on how the different bacterial groups were pooled together was described in section 2.5 (Line 146-154). The bacterial peptides were extracted from the N. gonorrhoeae according to a previous study with slightly modification [11]. Briefly, 5% (v/v) trifluoroacetic acid (TFA) in absolute acetonitrile (ACN) was added to the culture and the suspension was dissolved by gentle vortexing. The samples were dried and resuspended with 0.1% (v/v) formic acid. The Lowry assay was used to determine peptide concentration [12]. Peptides were equally pooled from each bacterium within the same group. Peptidome samples of each bacterial group including azithromycin resistance group (AZ), ciprofloxacin resistance group (C), ciprofloxacin and penicillin resistance group (CP), ciprofloxacin and tetracycline resistance group (CT), ciprofloxacin, penicillin and tetracycline resistance group (CPT) were analyzed by LC-MS.

9. Line 300, use the word "consistent"

Ans. Line 300 is corrected by the Professional editor under the program of Research clinic that supported by Faculty of Allied Health Sciences Thammasat University.

10. IMPORTANT COMMENT: There appears to be a significant missing link in the results presented in this study. The results obtained in the MIC determination using the E-test strip is not shown. The authors should present the result and further correlate with the peptidome obtained for the bacterial isolates. This will provide a further validation of the use of the MALDI-TOF as suggested by the authors.

Ans. The correlation between MICs and peptide barcode is not performed because of broad range of MICs of each bacterial group especially ciprofloxacin and penicillin resistance group (CP), ciprofloxacin and tetracycline resistance group (CT), ciprofloxacin, penicillin and tetracycline resistance group (CPT). Therefore, this study showed that MALDI-TOF peptide barcoding can be used to differentiate between AZ, C, CP, CT and CPT. In addition, LC-MS is used to quantitate and identify potential peptide candidates associated with the multidrug resistant N. gonorrhoeae.

Reviewer #4:

1. There are some language and grammatical errors throughout the manuscript text that should be corrected.

Ans. This manuscript was corrected by The Professional editor under the program of Research clinic that supported by Faculty of Allied Health Sciences Thammasat University.

2. Please define the abbreviations at the first mention of them in the text for example, IRB in line 93; PPNG: in line 97.

Ans. Institutional Review Board (IRB) (Line 94) and penicillinase-producing Neisseria gonorrhoeae (PPNG) were added (Line 96-97).

3. The data of Table 1 is repeated in the text, so this table could be deleted.

Ans. Table 1 is deleted as suggested.

________________________________________

________________________________________

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Benjamin M. Liu, Editor

PONE-D-23-07664R1Peptide barcode of multi drug resistant strains of Neisseria gonorrhoeae isolated from patients in ThailandPLOS ONE

Dear Dr. Arpornsuwan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 20 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-emailutm_source=authorlettersutm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Benjamin M. Liu, MBBS, PhD, D(ABMM), MB(ASCP)

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Summary:The issues raised in the previous review have been addressed adequately. The manuscript is also presented in intelligible fashion.

Minor issue:

1.The authors could mention the limitations of the study, the MALDI TOF MS in particular as mentioned in the response to reviewers "However, the specific antibiotic resistance peptides on MALDI-TOF mass spectra are difficult to identify due to their low abundance or high molecular weights"

Reviewer #2: (No Response)

Reviewer #4: The authors have adequately addressed all my comments raised in the previous round of review and I think this manuscript is now acceptable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Shivankar Agrawal

Reviewer #4: Yes: Mohammad Hossein Ahmadi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

PONE-D-23-07664R1

Peptide barcode of multidrug resistant strains of Neisseria gonorrhoeae isolated from patients in Thailand

Journal requirements

1. The reference list in line 509-551 has been changed from no 27-37, The reference number 27 was added in line 322 and in line 509 for reference list. The front color of reference no 26 in line 506 was formatted. All References were reviewed and corrected to be complete.

27. Karas M., Glückmann M., Schäfer J. Ionization in Matrix-Assisted Laser Desorption/Ionization: Singly Charged Molecular Ions Are the Lucky Survivors. J. Mass Spectrom. 2000; 35:1–12. doi: 10.1002/(SICI)1096-9888(200001)35:11::AID-JMS9043.0.CO;2-0

2. We upload all new copy of Figures following by PACE.

Response to Reviewers

Reviewer #1: Summary: The issues raised in the previous review have been addressed adequately. The manuscript is also presented in intelligible fashion.

Minor issue:

1. The authors could mention the limitations of the study, the MALDI TOF MS in particular as mentioned in the response to reviewers "However, the specific antibiotic resistance peptides on MALDI-TOF mass spectra are difficult to identify due to their low abundance or high molecular weights"

Answer: The sentences regarding the limitations of the study were added in line 320-328. “Although the application of MALDI-TOF MS for identification of microorganisms has been successful, the single laser MALDI approach produces low ion yield resulting in missing low abundant or hardly ionizable molecules [27]. The low-resolution associated with the linear TOF analyzers and the related mass accuracy might limit the discovery of peptide biomarkers. In addition, MALDI-TOF MS does not allow de novo peptide sequencing in terms of resolution and ability to perform peptide fragmentation and hence identify those specific peptide peaks. According to the limitations of MALDI-TOF MS, mass spectra linked directly to specific antibiotic resistance peptides are difficult to identify. LC-MS/MS was therefore used to identify and quantify potential antimicrobial resistance peptides.”

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Benjamin M. Liu, Editor

Peptide barcode of multi drug resistant strains of Neisseria gonorrhoeae isolated from patients in Thailand

PONE-D-23-07664R2

Dear Dr. Arpornsuwan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Benjamin M. Liu, MBBS, PhD, D(ABMM), MB(ASCP)

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Formally Accepted
Acceptance Letter - Benjamin M. Liu, Editor

PONE-D-23-07664R2

Peptide barcode of multidrug-resistant strains of Neisseria gonorrhoeae isolated from patients in Thailand

Dear Dr. Arpornsuwan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Benjamin M. Liu

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .